Provides preliminary fiscal 2026 revenue guidance of $79 to $82 million and adjusted diluted EPS guidance of $1.03 to $1.10
Fourth quarter and fiscal year 2025 results to be reported December 1, 2025
Simulations Plus to Participate in Upcoming Investor Conferences
Simulations Plus to Participate in Upcoming Investor Conferences
Simulations Plus and the Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor® Models with Enhanced AI Drug Design
Researchers found 70% of compounds designed in ADMET Predictor demonstrated significant activity during in vitro testing
Simulations Plus Invests in Clinical Development Technology Company Nurocor
Investment to accelerate innovations in biopharma development through Corporate Development Initiative
Simulations Plus Reports Third Quarter Fiscal 2025 Financial Results
Updated full-year revenue guidance of between $76 to $80 million and adjusted diluted EPS of $0.93 to $1.06
Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue
Updates fiscal 2025 revenue guidance range
Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET
Simulations Plus Announces Preliminary Third Quarter Fiscal 2025 Revenue
Updates fiscal 2025 revenue guidance range
Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET
Simulations Plus Releases ADMET Predictor® 13
Expanded functionality and advanced AI/ML capabilities deliver faster, more accurate predictions and streamline enterprise deployment
Simulations Plus Releases DILIsym® 11
Newest version of the quantitative systems toxicology (QST) software supports drug-induced liver injury (DILI) prediction for pediatric patient populations
Simulations Plus Supports New FDA Roadmap for Reducing Animal Testing in Preclinical Safety Studies
Modeling and simulation will be a key component for shift to non-animal methodologies
Introducing NAMVantage(TM), a flagship package offering PBPK and QSP professional services and regulatory strategy combined with built-in coaching and training
Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results
Total revenue grew 23% year-over-year driven by strong growth in both software and services
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum
Simulations Plus will be participating in a fireside chat at the KeyBanc Capital Markets Virtual Healthcare Investor.
Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements
Industry partners to provide funding and data to support ACAT™ model improvements
Simulations Plus Supported Development of Majority of FDA-Approved Drugs in 2024
SLP’s technology and expertise accelerates drug development and supports critical advancements in global healthcare
Simulations Plus Reports First Quarter Fiscal 2025 Financial Results
Total revenue up 31% year-over-year primarily driven by strong software growth
Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables
Funded collaboration will leverage current FDA partnership to include additional LAI technologies
Simulations Plus to Participate in the Stephens Annual Investment Conference
Simulations Plus to Participate in the Stephens Annual Investment Conference
Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations
Collaboration goal to develop alternative methods to assess clinical performance of product variants under different conditions
Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings
Partnership will advance the field of ligand-based virtual screening to improve drug design and optimization activities
Simulations Plus Releases DILIsym® X
Updated quantitative systems toxicology (QST) software investigates and predicts drug-induced liver injury (DILI)